M&A Deal Summary |
|
|---|---|
| Date | 2025-12-19 |
| Target | Amicus Therapeutics |
| Sector | Life Science |
| Buyer(s) | BioMarin Pharmaceutical |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.8B USD |
| Advisor(s) | Centerview Partners Goldman Sachs (Financial) Kirkland & Ellis (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 3,040 |
| Revenue | 2.9B USD (2024) |
BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. BioMarin Pharmaceutical was founded in 1996 and is based in San Rafael, California.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Add-on Acquisition M&A Deals | 4 of 4 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2025 M&A | 2 of 2 |
| Size (of disclosed) | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-05-16 |
Inozyme Pharma
Boston, Massachusetts, United States Inozyme Pharma is a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. The company's lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. It has demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency. Inozyme Pharma was formed in 2015 and is based in Boston, Massachusetts. |
Buy | $270M |
